https://www.palobiofarma.com/palobiofarma-completed-the-dose-escalation-part-of-the-phase-i-study-with-pbf-999-in-cancer-patients/ 2018-11-30T16:04:39+00:00 https://www.palobiofarma.com/wp-content/uploads/2018/10/october-2018.jpg https://www.palobiofarma.com/palobiofarma-achieves-first-patient-first-visit-in-two-key-phase-ii-studies/ 2018-11-30T16:04:43+00:00 https://www.palobiofarma.com/wp-content/uploads/2018/09/september-2018.jpg https://www.palobiofarma.com/palobiofarma-advances-its-broad-clinical-pipeline/ 2018-11-30T16:04:47+00:00 https://www.palobiofarma.com/wp-content/uploads/2018/03/march-2018.jpg https://www.palobiofarma.com/fda-grants-palobiofarma-approval-to-start-second-anti-cancer-study-in-usa/ 2018-11-30T16:04:50+00:00 https://www.palobiofarma.com/wp-content/uploads/2018/02/february-2018.jpg https://www.palobiofarma.com/palobiofarma-initiates-clinical-development-of-its-novel-dual-pde10-a2a-antagonist-in-solid-tumors/ 2018-11-30T16:04:55+00:00 https://www.palobiofarma.com/wp-content/uploads/2018/01/january-2018.jpg https://www.palobiofarma.com/palobiofarma-has-started-the-clinical-development-of-pbf-1650-2/ 2019-01-25T13:23:29+00:00 https://www.palobiofarma.com/xoma-and-inveready-acquires-royalty-interest-position-in-six-clinical-stage-assets-from-palobiofarma/ 2019-09-30T08:44:31+00:00 https://www.palobiofarma.com/june-8th-2020-palobiofarma-joins-the-fight-against-the-covid-19-pandemia/ 2020-06-08T10:25:35+00:00 https://www.palobiofarma.com/palobiofarma-announces-positive-results-from-the-phase-ii-clinical-trial-evaluating-the-preliminary-efficacy-and-safety-of-its-adenosine-a1-receptor-antagonist-pbf-680-in-mild-to-moderate-asthmatics-p/ 2020-09-03T07:35:14+00:00 https://www.palobiofarma.com/positive-clinical-results-of-palobiofarmas-adenosine-a1-antagonist-pbf-680-presented-at-the-european-respiratory-society-meeting/ 2020-09-07T12:01:29+00:00 https://www.palobiofarma.com/november-10th-2021-palobiofarma-announces-positive-results-in-the-phase-iia-clinical-trial-evaluating-its-first-in-class-investigational-treatment-pbf-677-in-patients-with-mild-to-moderate-ulc/ 2021-11-10T09:54:26+00:00 https://www.palobiofarma.com/september-09-2020-palobiofarma-announces-the-finalization-of-the-phase-iia-clinical-trial-of-its-first-in-class-investigational-treatment-pbf-677-in-patients-with-mild-to-moderate-ulcerative-c/ 2021-11-10T10:00:59+00:00 https://www.palobiofarma.com/december-16th-2021-palobiofarma-announces-that-it-has-been-included-among-the-99-innovative-companies-in-the-european-innovation-council-accelerator/ 2021-12-20T12:55:48+00:00 https://www.palobiofarma.com/wp-content/uploads/2021/12/EICAccelerator-October21cutoff_0-1.jpg https://www.palobiofarma.com/may-4-2023-palobiofarma-announces-a-collaboration-with-the-foundation-for-prader-willi-research-fpwr-for-the-development-of-pbf-999-as-a-novel-treatment-for-the-prader-willi-research-syndrome/ 2023-05-04T10:29:44+00:00 https://www.palobiofarma.com/palobiofarma-announces-the-enrolment-of-the-first-three-patients-in-the-clinical-study-investigating-the-effects-of-its-novel-compound-pbf-999-for-the-treatment-of-prader-willi-syndrome/ 2023-05-11T08:35:43+00:00 https://www.palobiofarma.com/palobiofarma-s-l-receives-rare-pediatric-disease-designation-from-the-u-s-fda-for-pbf-999-for-the-treatment-of-prader-willi-syndrome/ 2023-11-06T10:10:34+00:00 https://www.palobiofarma.com/palobiofarma-closes-a-e7m-round-with-the-participation-of-inveready-sodena-and-the-promotor-team/ 2024-02-12T13:32:28+00:00 https://www.palobiofarma.com/pbf-999-the-first-in-class-treatment-in-development-for-the-prader-willi-syndrome-has-received-orphan-drug-designation-by-the-european-medicines-agency-ema-and-the-us-food-and-dru/ 2024-03-04T16:57:00+00:00 https://www.palobiofarma.com/palobiofarma-announces-the-completion-the-phase-ii-clinical-trial-with-its-investigational-therapy-pbf-680-in-chronic-obstructive-pulmonary-disease-copd-patients/ 2024-04-19T07:21:48+00:00 https://www.palobiofarma.com/wp-content/uploads/2024/04/image.png https://www.palobiofarma.com/pamplona-spain-september-9th-2024-palobiofarma-is-pleased-to-announce-today-positive-top-line-results-in-a-phase-2-trial-of-the-novel-oral-drug-pbf-680-in-patients-with-moderate-to-severe-c/ 2024-09-09T07:23:36+00:00 https://www.palobiofarma.com/palobiofarma-and-medibiofarma-open-new-headquarters-in-the-ain-building-in-cordovilla-spain/ 2025-03-12T08:31:48+00:00 https://www.palobiofarma.com/wp-content/uploads/2025/03/Foto_equipo_Medi_Palobiofarma-scaled.jpg https://www.palobiofarma.com/palobiofarma-announce-several-important-milestones-dealing-with-the-clinical-development-of-pbf-999-for-prader-willi-syndrome/ 2025-10-29T08:33:39+00:00 https://www.palobiofarma.com/palobiofarma-announces-completion-of-dual-a2a-h3-receptor-antagonist-research-project-for-parkinsons-disease/ 2026-04-13T08:22:14+00:00 https://www.palobiofarma.com/palobiofarma-announces-significant-advances-in-the-clinical-development-of-pbf-999-for-prader-willi-syndrome/ 2026-05-11T14:51:07+00:00